Votrient
Generic Name
Pazopanib
Manufacturer
Novartis Pharmaceuticals
Country
Switzerland (original), various for generics
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| votrient 200 mg tablet | ৳ 388.10 | ৳ 11,643.00 |
Description
Overview of the medicine
Votrient (Pazopanib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy.
Uses & Indications
Dosage
Adults
800 mg once daily, without food (at least 1 hour before or 2 hours after a meal).
Elderly
No specific dosage adjustment required based on age, but monitor for adverse events.
Renal_impairment
No dosage adjustment needed for mild to moderate renal impairment. No data for severe impairment.
How to Take
Take orally once daily, without food (at least 1 hour before or 2 hours after a meal). Swallow tablets whole, do not crush or chew.
Mechanism of Action
Pazopanib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that blocks the activity of VEGFR-1, -2, -3, PDGFR-α/β, FGFR-1/3, c-Kit, LCK, FMS, and TrkB. This inhibition leads to anti-angiogenic and anti-tumor effects.
Pharmacokinetics
Onset
Not precisely defined, anti-tumor effects develop over time.
Excretion
Mainly fecal (64% as unchanged drug and metabolites), with <4% excreted renally.
Half life
Approximately 30.6 hours (range 8-58 hours).
Absorption
Oral bioavailability is variable (around 21-50%). Peak plasma concentrations occur 2-4 hours after administration.
Metabolism
Primarily hepatic, via CYP3A4, with minor contributions from CYP1A2 and CYP2C8.
Side Effects
Contraindications
- Hypersensitivity to pazopanib or any component of the formulation.
- Severe hepatic impairment (Child-Pugh C)
Drug Interactions
0
Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, indinavir): Avoid co-administration; if unavoidable, reduce pazopanib dose.
1
Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): Avoid co-administration as they can decrease pazopanib levels.
2
QT prolonging drugs (e.g., antiarrhythmics, antipsychotics): Increased risk of QT prolongation.
3
Drugs that increase gastric pH (e.g., PPIs, H2-receptor antagonists, antacids): Can decrease pazopanib absorption. Avoid antacids within several hours, consider H2RAs/PPIs taken at specific times.
Storage
Store at room temperature (20°C to 25°C), away from moisture and heat. Keep out of reach of children.
Overdose
No specific antidote. Manage overdose supportively. Observe for signs of hepatotoxicity, hypertension, and other adverse events.
Pregnancy & Lactation
Pregnancy: May cause fetal harm. Advise pregnant women of potential risk to fetus. Lactation: Unknown if excreted in human milk. Advise women not to breastfeed during treatment and for 2 weeks after the last dose.
Side Effects
Contraindications
- Hypersensitivity to pazopanib or any component of the formulation.
- Severe hepatic impairment (Child-Pugh C)
Drug Interactions
0
Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, indinavir): Avoid co-administration; if unavoidable, reduce pazopanib dose.
1
Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): Avoid co-administration as they can decrease pazopanib levels.
2
QT prolonging drugs (e.g., antiarrhythmics, antipsychotics): Increased risk of QT prolongation.
3
Drugs that increase gastric pH (e.g., PPIs, H2-receptor antagonists, antacids): Can decrease pazopanib absorption. Avoid antacids within several hours, consider H2RAs/PPIs taken at specific times.
Storage
Store at room temperature (20°C to 25°C), away from moisture and heat. Keep out of reach of children.
Overdose
No specific antidote. Manage overdose supportively. Observe for signs of hepatotoxicity, hypertension, and other adverse events.
Pregnancy & Lactation
Pregnancy: May cause fetal harm. Advise pregnant women of potential risk to fetus. Lactation: Unknown if excreted in human milk. Advise women not to breastfeed during treatment and for 2 weeks after the last dose.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months, refer to product label.
Availability
Hospital pharmacies, specialty pharmacies
Approval Status
FDA approved
Patent Status
Patent expired in many regions, generics available
Clinical Trials
Votrient has been studied in multiple clinical trials, including VEG105192 (RCC) and PALETTE (STS), demonstrating efficacy in increasing progression-free survival.
Lab Monitoring
- Liver function tests (ALT, AST, bilirubin) at baseline, then weekly for the first 6 weeks, then at weeks 9 and 12, and periodically thereafter.
- Blood pressure regularly.
- Thyroid function tests.
- Urinalysis for proteinuria.
- ECG and electrolytes (potassium, magnesium, calcium) for QT prolongation risk.
Doctor Notes
- Closely monitor LFTs, BP, and thyroid function.
- Educate patients on signs of hepatotoxicity and cardiovascular events.
- Dose adjustments may be necessary for adverse events.
Patient Guidelines
- Take as directed by your doctor.
- Do not stop taking without consulting your doctor.
- Report any severe side effects immediately.
- Avoid grapefruit and grapefruit juice.
- Take without food.
Missed Dose Advice
If a dose is missed, do not take it if it is less than 12 hours until the next scheduled dose. Take the next dose at the regular time. Do not take two doses at the same time.
Driving Precautions
May cause fatigue, dizziness, or vision disturbances. Exercise caution when driving or operating machinery.
Lifestyle Advice
- Maintain good hydration.
- Avoid alcohol and tobacco if possible.
- Follow a balanced diet.
- Discuss any changes in diet or supplements with your doctor.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Votrient Brand
Other medicines available under the same brand name
